Treatment non-persistence in children and adolescents with Tourette syndrome newly treated with dopamine D2 receptor modulators - Scorecard - MDSpire

Treatment non-persistence in children and adolescents with Tourette syndrome newly treated with dopamine D2 receptor modulators

  • By

  • Kinga K. Tomczak

  • Jason P. Swindle

  • Firas M. Dabbous

  • Donald L. Gilbert

  • George B. Karkanias

  • Sarah D. Atkinson

  • Frederick E. Munschauer

  • Faizan Mazhar

  • Charlotte A. Pettersson

  • Stephen P. Wanaski

  • Timothy M. Cunniff

  • David A. Isaacs

  • June 2, 2026

  • 0 min

Share

Clinical Scorecard: Adherence Challenges in Pediatric Patients with Tourette Syndrome Initiated on Dopamine D2 Receptor Modulators

At a Glance

CategoryDetail
Condition
Key MechanismsDopamine D2 receptor antagonists/partial agonists (D2RAs) including haloperidol, pimozide, aripiprazole, and other antipsychotics.
Target Population
Care Setting

Key Highlights

  • highlight_2

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Regular assessment of medication adherence and adverse events using validated tools.

      Risks

        Patient & Prescribing Data

        Children and adolescents aged 6 to 17 years with TS.

        D2RA treatment is associated with significant AEs and healthcare utilization.

        Clinical Best Practices

        • best_practice_4

        Related Resources & Content

        Original Source(s)

        Treatment non-persistence in children and adolescents with Tourette syndrome newly treated with dopamine D2 receptor modulators

        • by Kinga K. Tomczak, Jason P. Swindle, Firas M. Dabbous, Donald L. Gilbert, George B. Karkanias, Sarah D. Atkinson, Frederick E. Munschauer, Faizan Mazhar, Charlotte A. Pettersson, Stephen P. Wanaski, Timothy M. Cunniff, David A. Isaacs

        • June 2, 2026

        Related Content

        Diabetes Risk Scores: Beyond Glucose

        Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.

        New Label Expansion in Generalized Myasthenia Gravis

        Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.

        Ophthalmologic assessment and intracranial pressure in children: diagnostic methods, clinical correlations, and future directions